Weekly Analysts’ Ratings Changes for Braveheart Bio (BRVE)

Several brokerages have updated their recommendations and price targets on shares of Braveheart Bio (NASDAQ: BRVE) in the last few weeks:

• 8/31/2026 – Braveheart Bio is now covered by TD Cowen. They set a “buy” rating on the stock.
• 8/31/2026 – Braveheart Bio is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $48.00 price target on the stock.
• 8/31/2026 – Braveheart Bio is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $48.00 price target on the stock.
• 8/31/2026 – Braveheart Bio is now covered by Stifel Nicolaus. They set a “buy” rating and a $45.00 price target on the stock.
• 8/31/2026 – Braveheart Bio is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $40.00 price target on the stock.
• 8/15/2026 – Braveheart Bio was upgraded by Wall Street Zen to “hold”.

Insider Transactions at Braveheart Bio

In other Braveheart Bio news, major shareholder Growth Opportunities F. Forbion acquired 1,680,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was bought at an average price of $18.00 per share, with a total value of $30,240,000.00. Following the purchase, the insider owned 10,185,478 shares of the company’s stock, valued at approximately $183,338,604. This trade represents a 19.75% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Erez Chimovits bought 1,940,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $34,920,000.00. Following the transaction, the director owned 11,901,826 shares in the company, valued at $214,232,868. This trade represents a 19.47% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders purchased 8,751,942 shares of company stock worth $157,534,956.

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.